Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
Abstract Regular prophylaxis has markedly improved the treatment for patients with hemophilia A, especially after the introduction of highly purified factor VIII (FVIII) concentrates. However, frequent intravenous infusions and the development of FVIII inhibitors remain as unsolved difficulties. To...
Main Author: | Midori Shima |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-05-01
|
Series: | Research and Practice in Thrombosis and Haemostasis |
Subjects: | |
Online Access: | https://doi.org/10.1002/rth2.12337 |
Similar Items
-
Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
by: Renchi Yang, et al.
Published: (2022-02-01) -
Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report
by: Beth Boulden Warren, et al.
Published: (2021-07-01) -
Efficient production of bispecific antibody by FAST-IgTM and its application to NXT007 for the treatment of hemophilia A
by: Hikaru Koga, et al.
Published: (2023-12-01) -
Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience
by: Karla Rener, et al.
Published: (2023-11-01) -
Impact of novel hemophilia therapies around the world
by: Margareth C. Ozelo, et al.
Published: (2022-03-01)